Latest news with #UCB
Associated Press
02-06-2025
- Business
- Associated Press
Access Barriers Hamper Early Line Adoption of UCB's Bimzelx at Six Months Post-Launch in Psoriatic Arthritis and Axial Spondyloarthritis, According to Spherix Global Insights
EXTON, PA, June 02, 2025 (GLOBE NEWSWIRE) -- Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB's Bimzelx (bimekizumab) is demonstrating meaningful promise, though prescriber momentum remains tempered by access hurdles and payer-imposed constraints, according to new findings from Spherix Global Insights' Launch Dynamix™ services. Physicians across both PsA (n=76) and axSpA (n=73) have expressed strong clinical enthusiasm for Bimzelx, particularly citing its unique dual inhibition of IL-17A and IL-17F as a differentiator from existing IL-17 agents. In PsA, rheumatologists report confidence in the drug's performance across both skin and joint domains and consider it a therapeutic advance over competitors like Novartis' Cosentyx and Eli Lilly's Taltz. In axSpA, particularly among more severe or refractory patients, Bimzelx is increasingly viewed as a preferred IL-17, with some physicians already positioning it ahead of established options in terms of anticipated efficacy and breadth of benefit. Despite its favorable clinical profile, Bimzelx's adoption is constrained by a consistently challenging reimbursement environment. In PsA, nearly all prescriptions require prior authorization, with step therapy requirements and payer preferences for legacy agents continuing to block earlier use. These access challenges are echoed in AS and nr-axSpA, where physicians cite not only high out-of-pocket costs and Medicare limitations but also a general lack of formulary inclusion across plans. While some rheumatologists note success in early line use, many describe regular denials and delays that often force them to default to more accessible agents despite clinical preference for Bimzelx. As one rheumatologist summarizes, 'I like Bimzelx. The big headwind I'm facing now, it just gets denied by insurers. So commercial insurance coverage, which seems to always plague UCB products, is horrible. I'm hoping that will improve.' To address these access barriers, some physicians are turning to samples and bridge programs. However, in PsA, just 13% of patients initiated on Bimzelx started with a sample or free drug, with a pattern similarly observed in axSpA. While sampling and bridge programs are providing a critical means to initiate Bimzelx, physician sentiments support that these are often used to navigate around access hurdles, with uncertainty remaining around consistent conversion to insurance coverage and sustainability of this approach. While access barriers are a common thread, and also are common across many recently launched biologics in immunology, notable differences are emerging in how Bimzelx is being adopted and perceived across PsA versus axSpA. In PsA, two-thirds of rheumatologists have already prescribed Bimzelx, typically for patients with severe or flaring disease after failing multiple advanced therapies. Many express interest in moving the therapy earlier in the treatment algorithm but, again, remain limited by payer mandates. By contrast, adoption in axSpA is still ramping up, particularly in nr-axSpA, where just a minority of rheumatologists have used the product to date. Though uptake is slower, satisfaction levels remain high among those with prescribing experience, and many physicians expect to expand use as coverage improves. In addition to ramped trial and utilization, promotional efforts from UCB are beginning to resonate. The majority of rheumatologists report contact with Bimzelx sales representatives, who are largely praised for their professionalism and ability to communicate key efficacy and safety differentiators. However, a notable subset of physicians in both PsA and axSpA have yet to be detailed, and limited awareness of support services—such as the Bimzelx Navigate program—suggests more work is needed to fully activate the prescriber base. Those who have engaged with Navigate report a positive experience, citing timely support and ease of use, though these accounts remain limited. As the launches progress, the key question is whether UCB can convert strong clinical perceptions into real-world usage at earlier points in care. While Bimzelx is well-positioned from an efficacy standpoint, its long-term success will hinge on overcoming payer resistance and improving patient access. Spherix Global Insights will continue to track Bimzelx's PsA, AS and nr-AxSpA U.S. launch trajectory through its Launch Dynamix™ service through the first eighteen months of commercial availability. Launch Dynamix™ is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. Lynn Price, Rheumatology Franchise Head Spherix Global Insights 4848794284 [email protected]
Yahoo
19-05-2025
- Business
- Yahoo
UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
Collaboration Blends Advanced Cloud Technologies, Open-Source Collaboration, and Data Science Integration to support UCB's development pipeline BRUSSELS and SAN FRANCISCO, May 19, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, and Domino Data Lab, provider of a leading data science platform trusted by the world's largest enterprises, today announced a strategic collaboration aimed at modernizing a Statistical Computing Environment (SCE) for the life sciences industry. This joint effort aims to transform the legacy SCE into unified, scalable, and flexible platforms to meet the evolving demands of clinical research, regulatory compliance, and efficient data analysis. The two companies will work together to implement a modern cloud-enabled environment that integrates diverse analytical tools, such as SAS, R, and Python, within a unified framework. This platform will leverage Domino's expertise in cloud technologies and open-source support, combined with UCB's deep clinical research and regulatory knowledge. Together, this effort aims to enhance research capabilities and maintain compliance with industry standards like GxP, FDA 21 CFR Part 11, and GDPR. "At UCB, we believe that innovation thrives through collaboration, and this partnership exemplifies our commitment to evolving and pushing the boundaries of what's possible in life sciences. By harnessing advanced technologies to modernize our statistical computing environment and combining our expertise with Domino's cutting-edge platform, we aim to accelerate the development of innovative therapies for people living with severe diseases," said Mike Branson, SVP, Head Biometrics and Data Science, UCB. He added, "This new SCE will embed critical metadata and workflow management to enable searchable, responsible data re-use, accelerating our cutting-edge Data Science and enabling more efficient drug development and evidence-based decision making." The collaboration is aligned with UCB's broader scientific innovation strategy, which includes leveraging pathways, populations, and technology platforms to uncover the root biological causes of diseases, deepen understanding of patient populations, and accelerate R&D pipelines. "We're proud to partner with UCB to help patients get new therapies faster," said Nick Elprin, CEO and co-founder of Domino Data Lab. "Together, we aim to lead the way in modernizing Statistical Computing Environments to accelerate clinical development with greater speed, flexibility, and confidence." The modernized SCE will bring immediate benefits to researchers, data scientists, and patients by providing streamlined access to state-of-the-art tools. Enhancing UCB's capabilities in this way should expedite the development of differentiated therapies, offering faster, more tailored treatment options for those living with severe diseases. Additionally, the integration of advanced data science will enable more efficient clinical studies, leveraging large-scale data analysis to enhance predictions about efficacy and tolerability. This collaboration also emphasizes UCB and Domino's shared commitment to driving innovation across the life sciences industry. By contributing to initiatives like PHUSE, and the SCE Coalition, the partnership aims to foster open-source principles, challenge industry norms, and establish global standards for efficient and compliant statistical environments. Together, UCB and Domino are not only advancing their own operations but also paving the way for broader industry transformation. About UCB UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news. About Domino Data Lab Domino Data Lab empowers the largest data-driven enterprises to build and operate data science at scale. Domino's Enterprise Data Science Platform provides an integrated experience encompassing analysis and reporting, collaboration, and governance. With Domino, global enterprises can develop better medicines, grow more productive crops, develop more competitive products, and more. Founded in 2013, Domino is backed by Sequoia Capital, Coatue Management, NVIDIA, Snowflake, and other leading investors. Learn more at Investor RelationsUCB, Antje WitteT +32.2.559.94.14email Head of Global R&D and Business CommunicationsUCB, Scott FlemingT +447702777378email For Domino Data LabDavid ConnerT +1 415-907-0400email Forward looking statements This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document. Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring, retention and compliance of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems. Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB. UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. View original content to download multimedia: SOURCE Domino Data Lab; UCB Sign in to access your portfolio
Medscape
14-05-2025
- Health
- Medscape
Neighborhood May Affect HS Risk, Study Finds
A retrospective study found that individuals living in socioeconomically disadvantaged neighborhoods had a higher risk of developing hidradenitis suppurativa (HS), an association that persisted across racial and ethnic groups. METHODOLOGY: This cross-sectional analysis included 65,766 individuals (mean age, 50.4 years; 41.8% women; 56.5% White; 15.7% Asian, Native Hawaiian, or other Pacific Islander; 7.5% Hispanic; and 3.8% Black individuals) from dermatology clinics at the University of California San Francisco health system between August 2019 and May 2024. Neighborhood-level socioeconomic status (nSES) was assessed at the census tract level using a validated index derived from seven socioeconomic indicators. Patients were categorized into five nSES quintiles, with Q1 representing the lowest SES neighborhoods and Q5 the highest. The study outcome was HS diagnoses. TAKEAWAY: A total of 485 participants (0.7%) received a new HS diagnosis. The proportion of patients with HS was highest in Q1 (24.3%). After adjusting for age, sex, and race/ethnicity, the odds of an HS diagnosis decreased with each successive increase in nSES compared with the highest quintile (odds ratio, 3.32 for Q1, 2.25 for Q2, 1.97 for Q3, and 1.44 for Q4; P < .001 for linear trend). < .001 for linear trend). Race-stratified analyses showed consistently higher odds of HS diagnosis in lower SES neighborhoods among Black, Hispanic, and White individuals. Obesity partially mediated the association between nSES and HS diagnosis (adjusted proportion mediated, 0.17-0.35 across all quintiles). IN PRACTICE: 'This cross-sectional study found that nSES was independently associated with a new diagnosis of HS in dermatology patients,' the study authors wrote. This finding, they added, 'supports the hypothesis that neighborhood-level factors may influence the development of HS.' SOURCE: The study was led by Aileen Y. Chang, MD, University of California San Francisco School of Medicine, and was published online on May 14 in JAMA Dermatology . LIMITATIONS: The generalizability of the effect size could be limited outside of the San Francisco Bay Area. Other limitations were selection bias, missing data, underpowered subgroup analyses, cross-sectional design. Also, nSES was assessed only at the index visit. DISCLOSURES: The study received support from the University of California San Francisco Academic Research Systems and the National Center for Advancing Translational Sciences of the National Institutes of Health. Chang and another author disclosed receiving support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases for this study. Two authors declared receiving personal fees from Abbvie, Medscape, Novartis, UCB, and Sonoma Biotherapeutics, Aurinia, UCB, and AstraZeneca and serving as vice president of the Hidradenitis Suppurativa Foundation.
Globe and Mail
04-04-2025
- Health
- Globe and Mail
Lennox-Gastaut syndrome Market to Expand Significantly by 2034, States DelveInsight Report
The Lennox–Gastaut syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lennox–Gastaut syndrome pipeline products will significantly revolutionize the Lennox–Gastaut syndrome market dynamics. DelveInsight's 'Lennox–Gastaut syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Lennox–Gastaut syndrome, historical and forecasted epidemiology as well as the Lennox–Gastaut syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Lennox–Gastaut syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. To Know in detail about the Lennox–Gastaut syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lennox–Gastaut syndrome Market Forecast Some of the key facts of the Lennox–Gastaut syndrome Market Report: The Lennox–Gastaut syndrome market size was valued ~596 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In June 2024, UCB, a global biopharmaceutical company, announced that Epilepsia published results from a comprehensive scoping review evaluating the effectiveness of FINTEPLA® (fenfluramine) in reducing the frequency of generalized tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) in patients with developmental and epileptic encephalopathies (DEEs). The review demonstrated a significant reduction in both GTCS and TCS across various DEEs, further supporting the data from the FINTEPLA clinical trial program. FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for treating seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients aged two years and older. In June 2024, Takeda (TSE:4502/NYSE:TAK) has announced topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase 3 trial that assessed soticlestat (TAK-935) in combination with standard care versus placebo plus standard care in patients with refractory Dravet syndrome (DS). While soticlestat did not meet the primary endpoint of reducing convulsive seizure frequency compared to placebo (p-value = 0.06), it showed clinically meaningful and nominally significant results in six key secondary endpoints, including responder rates, caregiver and clinician global impressions of improvement, and seizure intensity and duration scales during the 16-week treatment period (all p-values ≤ 0.008). DelveInsight's analysis forecasts that the Lennox-Gastaut Syndrome market will expand at a CAGR of 4.5% from 2024 to 2034. According to DelveInsight's epidemiology model, there were approximately 115,000 prevalent cases of Lennox-Gastaut Syndrome in the 7MM in 2023. This figure is expected to increase over the forecast period (2024-2034), largely due to heightened awareness and advancements in diagnostic methods. In 2023, the diagnosed prevalent cases of Lennox-Gastaut Syndrome across the 7MM totaled approximately 81,000. This number is expected to increase throughout the forecast period. In 2023, the United States recorded the highest number of diagnosed prevalent cases of Lennox-Gastaut Syndrome, with around 34,000 cases, a figure projected to rise throughout the forecast period. In 2023, the diagnosed prevalent cases of Lennox-Gastaut Syndrome in the US were distributed by gender, with males representing about 25,000 cases and females accounting for approximately 9,000 cases. In 2023, among the EU4 and the UK, Germany recorded the highest number of diagnosed prevalent cases of Lennox-Gastaut Syndrome, with roughly 11,000 cases. France followed with approximately 9,600 cases, and Italy had around 8,800 cases. In 2023, Japan had the fewest diagnosed prevalent cases of Lennox-Gastaut Syndrome, with around 3,000 cases. Key Lennox–Gastaut syndrome Companies: Takeda /Ovid, SK Life Science, Inc., Epygenix, CuroNZ Ltd, Eisai, and others Key Lennox–Gastaut syndrome Therapies: Soticlestat, Carisbamate, EPX-100, NRP2945, Fycompa, TAK-935/OV935 (Soticlestat), and others The Lennox–Gastaut syndrome epidemiology based on gender analyzed that Lennox–Gastaut syndrome is found to be more prevalent in males than in females, for some undefined reason, with the male to female ratio being 1:6 (relative risk, 5.31). Lennox–Gastaut syndrome Overview Lennox-Gastaut syndrome (LGS) is a rare and severe form of epilepsy that typically begins in early childhood, often between ages 3 and 5. It is characterized by multiple types of seizures, including tonic (stiffening) and atonic (loss of muscle tone) seizures. People with LGS also experience developmental delays, cognitive impairments, and behavioral issues. The causes of LGS can vary, including genetic factors, brain injury, or other underlying conditions. Treatment usually involves a combination of medications, and in some cases, surgery or dietary therapies, to manage the seizures and improve quality of life. Get a Free sample for the Lennox–Gastaut syndrome Market Report - Lennox–Gastaut syndrome Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Lennox–Gastaut syndrome Epidemiology Segmentation: The Lennox–Gastaut syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Lennox–Gastaut syndrome in the 7MM Total Diagnosed Prevalent Cases of Lennox–Gastaut syndrome in the 7MM Gender-specific Diagnosed Prevalent Cases of Lennox–Gastaut syndrome in the 7MM Seizures-specific Diagnosed Prevalent Cases of Lennox Gastaut syndrome in the 7MM Download the report to understand which factors are driving Lennox–Gastaut syndrome epidemiology trends @ Lennox–Gastaut syndrome Epidemiological Insights Lennox–Gastaut syndrome Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lennox–Gastaut syndrome market or expected to get launched during the study period. The analysis covers Lennox–Gastaut syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Lennox–Gastaut syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Lennox–Gastaut syndrome Therapies and Key Companies To know more about Lennox–Gastaut syndrome treatment, visit @ Lennox–Gastaut syndrome Medications Lennox–Gastaut syndrome Market Strengths The use of off-label branded and generic prescription medications targeted at individual symptoms of LennoxGastaut syndrome (LGS) Lennox–Gastaut syndrome Market Opportunities New therapeutic options are needed to address the unmet need for effective and curative therapies for Lennox-Gastaut syndrome (LGS). Scope of the Lennox–Gastaut syndrome Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Lennox–Gastaut syndrome Companies: Takeda /Ovid, SK Life Science, Inc., Epygenix, CuroNZ Ltd, Eisai, Takeda, Ovid, and others Key Lennox–Gastaut syndrome Therapies: Soticlestat, Carisbamate, EPX-100, NRP2945, Fycompa, TAK-935/OV935 (Soticlestat), and others Lennox–Gastaut syndrome Therapeutic Assessment: Lennox–Gastaut syndrome current marketed and Lennox–Gastaut syndrome emerging therapies Lennox–Gastaut syndrome Market Dynamics: Lennox–Gastaut syndrome market drivers and Lennox–Gastaut syndrome market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Lennox–Gastaut syndrome Unmet Needs, KOL's views, Analyst's views, Lennox–Gastaut syndrome Market Access and Reimbursement Table of Contents 1. Lennox–Gastaut syndrome Market Report Introduction 2. Executive Summary for Lennox–Gastaut syndrome 3. SWOT analysis of Lennox–Gastaut syndrome 4. Lennox–Gastaut syndrome Patient Share (%) Overview at a Glance 5. Lennox–Gastaut syndrome Market Overview at a Glance 6. Lennox–Gastaut syndrome Disease Background and Overview 7. Lennox–Gastaut syndrome Epidemiology and Patient Population 8. Country-Specific Patient Population of Lennox–Gastaut syndrome 9. Lennox–Gastaut syndrome Current Treatment and Medical Practices 10. Lennox–Gastaut syndrome Unmet Needs 11. Lennox–Gastaut syndrome Emerging Therapies 12. Lennox–Gastaut syndrome Market Outlook 13. Country-Wise Lennox–Gastaut syndrome Market Analysis (2020–2034) 14. Lennox–Gastaut syndrome Market Access and Reimbursement of Therapies 15. Lennox–Gastaut syndrome Market Drivers 16. Lennox–Gastaut syndrome Market Barriers 17. Lennox–Gastaut syndrome Appendix 18. Lennox–Gastaut syndrome Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Yahoo
21-03-2025
- Business
- Yahoo
Why Incyte Stock Was Tanking This Week
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days. The gloom this produced was pushing the biotech's share price down by nearly 11% week to date as of Friday before market open. On Monday, Incyte published the top-line results from two phase 3 trials of its povorcitinib, a treatment aimed at combating moderate to severe hidradenitis suppurativa (HS), also known as acne inversa. This is a chronic and inflammatory skin condition that can result in scarring, among other complications. In each of the trials, the drug met its primary endpoint of a significant (50%-plus) reduction from baseline in abscess and inflammatory nodule count versus a placebo, with no advances in abscess or draining tunnel count. Both of the tested doses achieved similar results. Although the biotech touted this as a success, some analysts were expecting better, given the drug's encouraging performance in phase 2 trials. If eventually approved and commercialized, povorcitinib will have competition, particularly with UCB's well-established and Food and Drug Administration-approved Bimzelx. Nevertheless, Incyte asserted that the phase 3 trials support its planned regulatory submission of its investigational drug. Biotechs are always heavily dependent on their pipeline, even commercial-stage ones like Incyte that already have approved medicines on the market. Povorcitinib still might be approved, given its performance against the placebo; however, at the moment, it isn't looking like much of a breakthrough medication. Before you buy stock in Incyte, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Incyte wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $726,481!* Now, it's worth noting Stock Advisor's total average return is 835% — a market-crushing outperformance compared to 164% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of March 18, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Incyte. The Motley Fool has a disclosure policy. Why Incyte Stock Was Tanking This Week was originally published by The Motley Fool Sign in to access your portfolio
